Given the location, combined with slight bony remodeling of the jugular foramen suggestive of a slow growing lesion, the appearance was thought to be consistent with a glomus jugulare tumor (Fig 2).

Glomus jugulare tumors present unique challenges due to multiple lower cranial nerve involvement, combined with ability to hypersecrete catecholamines and predilection to embolize intraoperatively.

Belzutifan is under clinical development by Merck and currently in Phase II for Paraganglioma (Glomus Jugulare Tumor). According to GlobalData, Phase II drugs for Paraganglioma (Glomus Jugulare Tumor) ...

VMT-a-NET is under clinical development by Perspective Therapeutics and currently in Phase II for Paraganglioma (Glomus Jugulare Tumor). According to GlobalData, Phase II drugs for Paraganglioma ...